Cabaletta Bio, Inc. financial data

Symbol
CABA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2929 Arch Street, Suite 600, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.16K % -20.1%
Debt-to-equity 10.1 % +14.2%
Return On Equity -50.1 % -6.48%
Return On Assets -45.5 % -5.28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.9M shares +14.1%
Common Stock, Shares, Outstanding 48.9M shares +17.3%
Entity Public Float 494M USD +1603%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1.17M shares -71.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 89.1M USD +76.7%
General and Administrative Expense 25.4M USD +46.2%
Operating Income (Loss) -115M USD -68.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -104M USD -66.7%
Earnings Per Share, Basic -2.15 USD/shares -25.7%
Earnings Per Share, Diluted -2.15 USD/shares -25.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 171M USD +47.7%
Cash, Cash Equivalents, and Short-term Investments 183M USD +11.3%
Assets, Current 186M USD +11.6%
Property, Plant and Equipment, Net 2.81M USD +41.4%
Operating Lease, Right-of-Use Asset 13.6M USD +229%
Other Assets, Noncurrent 2.48M USD +152%
Assets 204M USD +18%
Accounts Payable, Current 2.18M USD -39.8%
Employee-related Liabilities, Current 5.12M USD +64.6%
Liabilities, Current 22.9M USD +116%
Operating Lease, Liability, Noncurrent 7.29M USD +317%
Liabilities 30.2M USD +144%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -317M USD -49.1%
Stockholders' Equity Attributable to Parent 174M USD +8.28%
Liabilities and Equity 204M USD +18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -90.3%
Net Cash Provided by (Used in) Financing Activities 6.86M USD +2933%
Net Cash Provided by (Used in) Investing Activities -812K USD -103%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 48.9M shares +17.3%
Deferred Tax Assets, Valuation Allowance 72.6M USD +46%
Deferred Tax Assets, Gross 74M USD +44.6%
Operating Lease, Liability 0 USD
Depreciation 393K USD +7.67%
Payments to Acquire Property, Plant, and Equipment 812K USD +114%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -104M USD -67.2%
Lessee, Operating Lease, Liability, to be Paid 15.2M USD +257%
Property, Plant and Equipment, Gross 6.34M USD +28.1%
Operating Lease, Liability, Current 7.94M USD +215%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +34.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.76M USD +403%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.25M USD +120%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments Due, Next Twelve Months 2.28M USD
Deferred Tax Assets, Net of Valuation Allowance 1.45M USD -2.88%
Operating Leases, Future Minimum Payments Due 5.02M USD -2.34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%